{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-037345","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.142750+00:00","generated_at":"2026-06-15T12:59:25.077601+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius raises ~$15M via registered direct offering of 12.5M shares and warrants","bullets":["Issued 12.5M shares and warrants to purchase 12.5M shares at $1.20/unit in registered direct offering.","Gross proceeds ~$15M; net proceeds for general corporate purposes, including clinical development.","Warrants have exercise price $1.50, exercisable six months after issuance, expire in five years.","H.C. Wainwright acted as placement agent; cash fee ~$1.05M plus expenses and placement agent warrants.","Offering closed May 8, 2023; 60-day lock-up on further equity issuance and one-year restriction on floating-price securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-037345","json":"https://secwatch.observer/filing/0001213900-23-037345.json","markdown":"https://secwatch.observer/filing/0001213900-23-037345.md","text":"https://secwatch.observer/filing/0001213900-23-037345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/0001213900-23-037345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/ea178024-8k_citiuspharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:59:25.077601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31aacb7215a98f77e6469e938dcc934128384871","claim":"Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at combined offering price of $1.20 (effective 2023-05-03).","evidence_excerpt":"On May 3, 2023, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 12,500,001 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 12,500,001 shares of common stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023037345/0001213900-23-037345-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"combined offering price of $1.20"},{"label":"Effective","value":"2023-05-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}